Do you have news you would like to share on the NIVAS News Hub?
If you have an RSS feed you wish to share with up please contact us here.
Showing 1-12 of 1221 results.
"Significant variability in prevention and management of CA-DVT is reported among PC4 centers. Only half of respondent PC4 centers reported having an established treatment protocol for CA-DVT" Kim et al (2025).
"The primary objective of this study was to explore the relationship between compliance with national standards and PIVC-related sleep disturbance" Brijball et al (2025).
"Assuming universal real-time ultrasound-guided central venous catheterization, subclavian access retains lower infectious and thrombotic risk without an observed increase in mechanical complications, supporting its preferential use in intensive care units" Boulet et al (2025).
"To estimate the changes in total cost and health benefits associated with a decision to adopt 7-day vs standard 4-day replacement intervals via decision-analytic modeling" Elangovan et al (2025).
"OPAT was confirmed to be clinically robust and well tolerated, with additional potential benefits in preserving weight, frailty status, and cognitive well-being. These findings suggest that OPAT not only ensures infection control but may also protect against hospitalization-related functional decline" Ciusa et al (2025).
"Even peripheral IV cannulation may precipitate UEDVT when combined with local vein injury and systemic hypercoagulability. Antipsychotics, such as haloperidol and chlorpromazine, may further elevate thrombosis risk" Kwesiga et al (2025).
New Open Access publication on A GAVeCeLT bundle for chest-port insertion: The SIC-Port protocol from the Journal of Vascular Access A GAVeCeLT bundle for chest-port…
Continue reading → A GAVeCeLT bundle for chest-port insertion: The SIC-Port protocol
"DTX monotherapy-related EV occurs in 0.075% of cancer patients. The proportion of patients with a history of EV was higher among those who experienced EV than among the overall study population. Only a small proportion of patients who develop EV are prescribed topical steroids or receive consultation from the dermatology or plastic surgery department" Yanagisawa et al (2025).
"A 30 × 109/L platelet transfusion threshold appears safe for pediatric CVC insertion. Emphasizing procedural bundles and simulation-based operator training may reduce transfusion needs, associated risks, and costs" Raffaele et al (2025).
"When comparing the rate of early discontinuation between daptomycin and vancomycin in OPAT, there was no significant difference between groups. These findings suggest that either agent may be considered in the OPAT setting depending on patient-specific factors" Lanier et al (2025).
"There are associated adverse effects with intravenous (IV) vancomycin, yet there is a paucity of published literature surveying the appropriateness of use. The objective of the study was to assess the appropriateness of IV vancomycin prescriptions at a Canadian acute care hospital" Glassman et al (2025).
"Given the complexity of administration, limited stability data, and cost of these regimens, completing a 6-week course of therapy at home is challenging for both patients and OPAT programmes" White and Siegrist (2025).
